When trastuzumab binds to HER2-expressing tumor cells, T-DXd is internalized and the payload is released into cancer cells, penetrating neighboring cancer cells that do not express HER2 through a bystander effect, while circulating HER2-expressing tumor cells also release deruxtecan and remained stable in the periphery [178,179]. Here, ERBB2 is linked to neoplasm.